|Bid||284.01 x 1000|
|Ask||288.99 x 1000|
|Day's Range||285.49 - 291.36|
|52 Week Range||268.62 - 380.76|
|Beta (3Y Monthly)||1.20|
|PE Ratio (TTM)||45.44|
|Earnings Date||Oct 21, 2019 - Oct 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||322.57|
Soil biome health analysis company Biome Makers Inc. has closed a $4 million venture round from European investors.
Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.
Reported on by Bloomberg’s Scarlet Fu, take a look at the ARK Genomic Revolution ETF (ARKG) if you are looking for an ETF that goes after companies involved in the genomics industry. Functioning as an ...
Picture a bizarre clothing store for a moment …Source: Shutterstock You walk in. An employee sizes you up and asks you if there's anything in particular you're looking for. After learning that you're a size "large" and that you'd like some new dress shirts, the employee takes you to a table covered with them. All of the shirts are the same size. All XL, extra-large."Strange," you think, and go to another table covered with shirts. All the shirts are the same size. All XL.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"Stranger," you think, and go to another table covered with shirts. Once again, all the shirts are the same size. All XL.Sensing your confusion, the employee explains the store's "one size fits all" policy. The owners know people come in many shapes and sizes, but XL is the only size of clothes they can get from their suppliers.You walk out of the "one size fits all" store, thinking it's one of the most ridiculous things you've ever seen.A "one size fits all" clothing store isn't much different than America's healthcare system.Lacking the resources to treat us as individuals -- with different genetic makeups, different diets, and living in different environments -- doctors frequently resort to treating patients with "one size fits all" procedures and medicines. And since most doctors rush patients in and out of the office to boost profits, the pressure to use sub-par, "one size fits all" treatments is massive.Don't get me wrong: Our approach to health and medicine is light years ahead of where it was in the 1800s. Bloodletting is no longer a "go to" move for doctors.However, many of the decisions made by today's healthcare professionals will look medieval when compared to the treatments of the near future. They simply don't take into account that every case is different -- that we are all unique. Take the drug commercials you see on television … which go on to list lots of horrible side effects of popular drugs (which don't work for everyone who takes them).Soon, we'll say goodbye to those types of treatments. That's because the age of customized, "precision" healthcare is getting started. The result will be a massively improved healthcare system … and some of the biggest wealth building opportunities of your life.In today's essay, I'll describe the three key innovations that will take us into the age of precision medicine. Investors will want to pay attention. In America, we spend $3.5 trillion -- about 18% of GDP -- on healthcare. When something big happens in healthcare, it creates giant ripple effects in the economy that enrich those who know what's happening. Trillion-Dollar Innovation 1: Genome SequencingEvery cell in your body has a set of genetic instructions that dictate what you look like, what your athletic abilities are, what your mental abilities are, what diseases you're likely to get, and dozens of other key things that make you YOU.This set of instructions is called your genome. Determining exactly what your genome says is a process called genome sequencing.In 2003, an international research organization called The Human Genome Project sequenced a human genome for the first time. The project's price tag was an enormous $3 billion.Thanks to incredible advances in computing power, that same sequencing can be performed today for less than $1,000. And in a few years the price will be as low as a dinner for two.Genome sequencing is a critical part of precision medicine because it allows medical professionals to get an incredibly detailed analysis of who you are. As a result of this information, doctors can recommend treatments that are right for you.Sixteen years ago, getting this kind of detailed information was prohibitively expensive. But now that costs are down more than 99% and poised to go down even more, genome sequencing is about to go mainstream.Genetic testing will become part of regular medical care … just like taking your pulse and your blood pressure. It's going to usher in an era of much more effective healthcare. In large part to innovation 2 … Trillion-Dollar Innovation 2: Digital Patient RecordsIt's one thing to have lots of information. It's an entirely different -- and more valuable -- thing to be able to analyze that information and use it to make quality decisions.This is where digital patient records come in.Genome sequencing will produce vast amounts of information that will need to be stored and analyzed. Just as the processing power of our computers has increased by leaps and bounds since 2003, our ability to collect and store information has increased as well. This continued growth is a key part of precision medicine. That's because genome sequencing is going to generate a stupendous amount of information.It is predicted that the amount of storage capacity for all human genome data will increase to 40 exabytes by 2025. To put that into perspective, experts believe all videos on YouTube will require 1-2 exabytes of storage and Twitter will require .001 to .017 exabytes.As for analyzing all that data, we come to Innovation 3 … Trillion-Dollar Innovation 3: AI DoctorsAs you can guess, we're not going to sift through some of the world's largest data sets with a pen and paper in hand.We're going to use artificial intelligence (AI) to perform advanced data analysis. AI programs will sift through data to identify treatments that work for patients with specific genetic conditions.These programs will be able to do more "thinking" in one minute than millions of doctors could do in a decade. It's going to revolutionize healthcare.In fact, I believe that within the next 30 years, AI will know how various combinations of molecules will affect patients on the individual level. We'll have giant databases of patients and their genetic makeups … and we'll be able to test new drugs with computer simulations. The time it takes to devise, test, and produce new life-saving drugs will be massively condensed. Plus, the cost of doing it all will plummet.We'll have vast databases of human genomes and the ability to create and test new customized treatments in seconds. It could easily become the most valuable technology on the planet. Again, this is many years away, but I believe it's going to happen. Summing UpOne size fits allThanks to the technological limitations of the past, our healthcare system is based on treatments that are not tailored to your genetic makeup. We're using "shotgun" approaches instead of targeted approaches.However, thanks to cheap and widespread genome sequencing, digital record keeping, and artificial intelligence, we're about to enter an amazing era of precision, personalized medicine.Over the next 20 years, the healthcare system we know and don't love will change dramatically. We'll look back at some of today's treatments as medieval.Remember: In America, we spend $3.5 trillion -- about 18% of GDP -- on healthcare. When something big happens in the industry, it creates giant ripple effects. That's why the precision medicine revolution is one of the greatest wealth building opportunities of your life.The opportunities are not in the old school big pharma names like Johnson & Johnson. They are in precision medicine and the technologies that will enable it.Everything from digital records company Cerner (NASDAQ:Cern) to gene testing pioneer Illumina (NASDAQ:ILMN) to contract research services firm IQVIA Holdings (NYSE:IQV) will take the lead in the future of precision medicine.And keep an eye on the IPO market here as well. We'll see waves of early stage companies going public … many with the potential to not only revolutionize medicine, but revolutionize your net worth as well.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip * 7 Services Stocks to Buy for the Rest of 2019 * 6 Stocks to Buy and 1 to Sell Based on Insider Trading The post 3 Keys to Investing in Next-Gen Healthcare Stocks appeared first on InvestorPlace.
President and CEO of Illumina Inc (30-Year Financial, Insider Trades) Francis A Desouza (insider trades) sold 3,000 shares of ILMN on 08/01/2019 at an average price of $301.25 a share. Continue reading...
I've been keeping an eye on Illumina, Inc. (NASDAQ:ILMN) because I'm attracted to its fundamentals. Looking at the...
The genomic sequencing company reported slower revenue growth because of several issues, including a delay in closing a major population genomics deal.
Illumina (ILMN) delivered earnings and revenue surprises of 2.27% and 0.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Illumina on Monday reported adjusted earnings of $1.35 per share on $838 million in sales for its second quarter ended June 30. Illumina's guidance for adjusted earnings in 2019 was light.
Illumina Inc. shares declined in the extended session Monday after the genetics technology company's revenue and outlook fell short of Wall Street expectations. Illumina shares fell 3.4% after hours, following a 1.2% rise in the regular session to close at $304.41. The company reported second-quarter net income of $296 million, or $1.99 a share, compared with $209 million, or $1.41 a share, in the year-ago period. Adjusted earnings were $1.35 a share. Revenue rose to $838 million from $830 million in the year-ago quarter. Analysts surveyed by FactSet had forecast earnings of $1.34 a share on revenue of $855.9 million. Illumina expects adjusted earnings of $6 to $6.10 a share and for revenue to grow about 6%, while analysts had forecast $6.38 a share and revenue of $3.62 billion, or a 8.7% year-over-year increase.
Investing.com - Illumina (NASDAQ:ILMN) reported second quarter earnings that matched analysts' expectations on Monday and revenue that fell short of forecasts.
Illumina (NASDAQ: ILMN ) releases its next round of earnings this Monday, July 29. Here's Benzinga's essential guide to Illumina's Q2 earnings report. Earnings and Revenue Illumina earnings will be near ...
Illumina, Inc. is expected to report net income of $201.8 million, or $1.34 a share, on sales of $855.9 million after the market closes on Monday, based on a FactSet survey of 16 analysts. Illumina is currently trading at a price-to-forward-earnings ratio of 43.5 based on the 12-month estimates of 17 analysts surveyed by FactSet. Introducing TheStreet Courses: Financial titans Jim Cramer and Robert Powell are bringing their market savvy and investing strategies to you.
Illumina, GW Pharmaceuticals, Paycom, Zscaler and Square highlighted as Zacks Bull and Bear of the Day
Illumina is set to report its Q2 earnings on Monday, July 29 and investors are waiting to see if there is anything that might help the stock recover from its recent fall.